Somatostatin Inhibits Diarrhea in the Carcinoid Syndrome

Abstract

Brief Reports1 January 1980Somatostatin Inhibits Diarrhea in the Carcinoid SyndromeKIERTISIN DHARMSATHAPHORN, M.D., ROBERT S. SHERWIN, M.D., SAMUEL CATALAND, M.D., BERNARD JAFFE, M.D., JOHN DOBBINS, M.D.KIERTISIN DHARMSATHAPHORN, M.D., ROBERT S. SHERWIN, M.D., SAMUEL CATALAND, M.D., BERNARD JAFFE, M.D., JOHN DOBBINS, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-92-1-68 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptRecent studies in rats indicate that somatostatin inhibits jejunal fluid secretion induced by prostaglandin E1 and theophylline in vivo (1) and the effect of vasoactive intestinal polypeptide on fluid transport in the colon in vitro (2). These findings suggest that somatostatin may ameliorate symptoms in patients with watery diarrhea syndromes by suppressing hormonal release or by blocking intestinal secretagogue effects. We report here that somatostatin has inhibited watery diarrhea in a patient with the carcinoid syndrome.A 64-year-old white woman with metastatic carcinoid tumor had a 5-year history of continuous refractory watery diarrhea. Examination revealed facial telangiectasia and hepatomegaly. All...References1. DHARMSATHAPHORNSHERWINBINDERDOBBINS KRHJ. Somatostatin inhibits intestinal fluid secretion. Clin Res. 1978;26:496A. Abstract. Google Scholar2. CARTERBITARZFASSMAKHLOUF RKAG. Inhibition of VIP-stimulated intestinal secretion and cyclic AMP production by somatostatin in the rat. Gastroenterology. 1978;74:726-30. CrossrefMedlineGoogle Scholar3. WISEHENDLERFELIG JRP. Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. J Clin Invest. 1973;52:2774-82. CrossrefMedlineGoogle Scholar4. KELLUMJAFFE JB. Validation and application of a radioimmunoassay for serotonin. Gastroenterology. 1976;70:516-22. CrossrefMedlineGoogle Scholar5. THOMASSHOOKO'DORISIO FDT. Localization of gastric inhibitory polypeptide release by intestinal glucose perfusion in man. Gastroenterology. 1977;72:49-54. CrossrefMedlineGoogle Scholar6. GAGINELLAMEKHJIANO'DORISIO THT. Vasoactive intestinal polypeptide: quantification by radioimmunoassay in isolated cells, mucosa, and muscle of the hamster intestine. Gastroenterology. 1978;74:718-21. CrossrefMedlineGoogle Scholar7. DHARMSATHAPHORNRACUSENDOBBINS KLJ. Somatostatin (SRIF) alters electrolyte transport in the rat colon. Gastroenterology. 1979;76:1121. Abstract. Google Scholar8. GERICHPATTON JG. Somatostatin: physiology and clinical applications. Med Clin North Am. 1978;62:375-92. CrossrefMedlineGoogle Scholar9. EFENDICMATTSSON SO. Effect of somatostatin on intestinal motility. Acta Radiol [Diagn] (Stockh). 1978;19:348-52. MedlineGoogle Scholar10. BINDER H. Fecal fatty acids—mediators of diarrhea. Gastroenterology. 1973;65:847-50. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Yale University School of Medicine New Haven, Connecticut PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByTargeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future PerspectivesInitiation of Patients onto Long-Acting Somatostatin Analogue Therapy for Neuroendocrine Tumors: A Single-Center Review of PracticeSomatostatin regulates NHE8 protein expression via the ERK1/2 MAPK pathway in DSS-induced colitis miceUpdate on management of midgut neuroendocrine tumorsThe untapped potential of Gallium 68-PET: The next wave of 68Ga-agentsUpdate on the Role of Somatostatin Analogs for the Treatment of Patients With Gastroenteropancreatic Neuroendocrine TumorsClinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)Pharmacological Management of DiarrheaMechanisms underlying modulation of monocarboxylate transporter 1 (MCT1) by somatostatin in human intestinal epithelial cellsTreatment of gastric carcinoidsCarcinoid TumorsOctreotide in the Management of Chemoradiotherapy-Induced Diarrhea Refractory to Loperamide in Patients with Rectal CarcinomaCurrent Status of Gastrointestinal CarcinoidsTumors and Tumor-like Lesions of the Colon, Rectum, Anus, and Perianal RegionTumoren und tumorartige Läsionen des Dickdarms, Anorektums und PerianalbereichsOctreotide in Pediatric PatientsSystematic review: the use of somatostatin or octreotide in refractory diarrhoeaEffect of somatostatin on electrogenic ion transport in the duodenum and colon of the mouse, Mus domesticusTumoren und tumorartige Läsionen des Dickdarms, Anorektums und PerianalbereichsCarcinoid tumours.Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patientsConsensus statement: Octreotide dose titration in secretory diarrheaReview article: anti-diarrhoeal pharmacology and therapeuticsClinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours Report on a double-blind, randomized trialDrug therapy in diarrheal diseases in oncology/hematology patientsImportance of Vasoactive Intestinal Peptide and Somatostatin for Fluid Losses in Small-Bowel ObstructionBiology and management of the midgut carcinoidControl of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracilOctreotide in the Treatment of Disorders of the Gastrointestinal SystemNeurohormonal Control of Fluid and Electrolyte Transport in Intestinal MucosaIntestinal absorption of the octapeptide SMS 201–995 visualized by fluorescence derivatizationTreatment of Amyloidosis Associated Diarrhea with a Somatostatin AnalogueSevere posthemicolectomy diarrhea: Evaluation and treatment with SMS 201-995The antisecretory effects of somatostatin and analogues in rat descending colon mucosaTumoren und tumorartige Läsionen des Dickdarms, Anorektums und PerianalbereichesSomatostatinEffect of a long acting somatostatin analogue SMS 201-995 on jejunostomy effluents in patients with severe short bowel syndrome.Treatment of secretory diarrhea in AIDS with the somatostatin analogue SMS 201-995Sandostatin® in Digestive Endocrine TumorsPre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndromeInvited commentaryIn vitro effects of the long-acting somatostatin analogue SMS 201–995 on electrolyte transport by the rabbit ileumCarcinoid Syndrome and Disorders of Systemic Mast-Cell Activation Including Systemic MastocytosisSuccessful treatment of idiopathic secretory diarrhea of infancy with the somatostatin analogue SMS 201-995Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndromeCarcinoids and carcinoid syndromePseudopancreatic cholera syndrome: effect of a synthetic somatostatin analogue, SMS 201-995Somatostatin analogue SMS 201-995 long term therapy for vipoma.Antidiarrheal therapyEscape of the response to a long-acting somatostatin analogue (SMS 201–995) in patients with VIPomaChronic administration of the somatostatin analogue SMS 201-995 does not lead to endogenous antibody formationSomatostatin in Gastrointestinal Function: Intestinal Absorption and SecretionTreatment of Gut-Associated Neuroendocrine Tumors with the Long-Acting Somatostatin Analog, SMS 201-995The Carcinoid SyndromeSubstance P-induced intestinal secretion of water and electrolytes.Tumoren und tumorartige Läsionen des Dickdarms, Anorektums und PerianalbereichesNeuroendocrine Tumours of the Gut: Long-Term Therapy with the Somatostatin Analogue SMS 201-995Short-Term Administration of the Somatostatin Analogue SMS 201-995 in Patients with Carcinoid TumoursLong-Term Treatment of Patients with Endocrine Gastrointestinal Tumours with the Somatostatin Analogue SMS 201-995Pancreatic Cholera Syndrome: Effect of a Synthetic Somatostatin Analog on Intestinal Water and Ion TransportWILLIAM C. SANTANGELO, M.D., THOMAS M. O'DORISIO, M.D., JONG G. KIM, M.D., GENE SEVERINO, M.D., GUENTER J. KREJS, M.D.Gastroenteropancreatic endocrine tumorsTreatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.Clinical Applications of Somatostatin AnalogsThe Effects of Somatostatin and Selected Analogs on Lipid Absorption in AnimalsIntestinal Somatostatin FunctionEctopic Hormone SyndromesEffect of intravenous somatostatin on stool output in diarrhea due to Vibrio choleraeTreatment of chronic secretory diarrhea of unknown origin by lithium carbonateEffect of somatostatin infusion on VIP-induced transport changes in the human jejunumRecent advances in pancreatic hormone research.Endokrine Tumoren des DünndarmsHormonell induzierte DiarrhöenEnterotoxigenic diarrhea: Mechanisms and prospects for therapyTherapieSomatostatin inhibition of glucagon-stimulated jejunal secretion in the dogPathophysiology of Diarrhoea: Alterations in Fluid and Electrolyte TransportSomatostatin stimulates coupled sodium chloride influx across the brush border of the rabbit ileumSomatostatin Inhibits Fluid Secretion in the Rat JejunumSomatostatin Stimulates Sodium and Chloride Absorption in the Rabbit IleumZelluläre Wirkungen von Somatostatin und Pirenzipin im Antrum der Ratte 1 January 1980Volume 92, Issue 1Page: 68-69KeywordsCarcinoid tumorCareers in researchColonDiarrheaHepatomegalyPatientsPolypeptidesProstaglandinSomatostatinType 1 diabetes Issue Published: 1 January 1980 Copyright©1980 American College of PhysiciansPDF DownloadLoading ...